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ABSTRACT 
 
Purpose: To evaluate if corneal collagen crosslinking carried out on patients with 
keratoconus, slows down or halts the progression of keratoconus. To determine 
which group of keratoconus patients benefited most from the procedure. 
 
Methods: A retrospective record review of 41 eyes of 29 patients. Visual acuity 
and keratometry measurements were recorded for the involved eye pre-
crosslinking and at 3 months and 6 months post-crosslinking. A comparison of 
these variables pre-crosslinking and at 6 months post-crosslinking was made to 
determine if there was a flattening of corneal curvature (keratometry readings) and 
an improvement in visual acuity. 
Patients were further divided into 3 groups of keratoconus, based on their 
keratometry readings (measured in diopters): mild keratoconus (≤47 diopters), 
moderate keratoconus (48 – 54 diopters) and advanced keratoconus (≥55 
diopters), to determine which group of keratoconus had the best keratometry 
reduction readings. 
 
Results: After crosslinking took place on 41 eyes, the UnVA of 16(39%) eyes 
showed an improvement at 6 months, 17(41%) eyes showed no change and 
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8(20%) eyes showed a decrease in UnVA at 6 months, compared to pre-CXL 
values. 
For BCVA, 12(29%) eyes showed an improvement at 6 months, 18(44%) eyes 
showed no change and 11(27%) eyes showed a decrease in BCVA at 6 months, 
compared to pre-CXL values. 
Keratometry readings however showed that 23(56%) eyes had an average 
flattening of corneal curvature readings of 0.7 D and the remaining 18(44%) eyes 
showed more steepening (worsening) of the corneal curvature readings of 0.9 D 
after 6 months post-CXL. 
30(73%) eyes had mild keratoconus, 7(17%) had moderate keratoconus and 
4(10%) had advanced keratoconus. 
19 of the 30 eyes in the mild keratoconus group (73%) showed an average 
flattening of corneal curvature of 0.6 D. 4 of the 7 eyes in the moderate 
keratoconus group (17%) showed an average flattening of corneal curvature of 0.7 
D. All 4 patients in the advanced group (10%) had steepening (worsening) of their 
corneal curvatures with an average of 1.2 D. 
 
Conclusion:  Corneal collagen crosslinking performed on keratoconus patients at 
least halts the progress of keratoconus. 6 months after CXL most patients showed 
minimal change from pre-CXL to 6 months in both visual acuity and keratometry. 
However a longer follow up period and larger sample size is needed to determine 
if vision and keratometry readings can improve significantly.  
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CHAPTER 1 
 
1.0 INTRODUCTION 
1.1 LITERATURE REVIEW     
Keratoconus is a progressive corneal ectasia (thinning). It is a potentially blinding 
condition in its advanced stages. Early diagnosis and management can prevent 
visual deterioration. 
The cornea is made up of six anatomical tissue layers. The stroma, which is the 
third layer, accounts for 90% of the corneal thickness and comprises primarily of 
collagen fibrils. These collagen fibrils are most vulnerable to weakening, which 
leads to keratoconus. Collagen fibrils are an interwoven network, orthogonally 
orientated (horizontal and vertical) to one another.1,2  
 
In keratoconic patients, this normal orthogonal orientation of collagen is 
redistributed due to the weak collagen fibrils.2 In order for the stromal collagen 
fibrils to regain strength, a procedure called corneal collagen crosslinking (CXL) 
needs to be performed. 
 
Keratoconus is one of the many corneal ectasias that is frequently seen.3 Its 
progressive nature usually begins during puberty, and has a slow disease 
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progression until the 3rd to 4th decade.4 Its hereditary role has not been fully 
determined.4 It has been associated with many systemic disorders, such as Down 
syndrome, Turner syndrome, Marfan syndrome and Ehlers Danlos syndrome.4 
Ocular associations includes vernal keratoconjunctivitis, aniridia (no iris), retinitis 
pigmentosa and chronic eye rubbing.3,5 
 
Patients with keratoconus have a reduced visual acuity because of the steep 
corneal curvatures that occur secondary to corneal thinning. By measuring corneal 
curvature (keratometry readings) in diopters (D), keratoconus can be grouped into: 
mild keratoconus (≤ 47 D), moderate keratoconus (48 – 54 D) and advanced 
keratoconus (≥55 D).2,5 
 
The corneas in keratoconus patients, typically take on a conical shape in the area 
of most corneal thinning.4 Classically this area of thinning is either central or 
paracentral.3,5 The collagen fibrils in this thinned area are non-orthogonally 
arranged.1 This is secondary to weak collagen bonds within the corneal stroma. It 
is also thought that the thinning is due to the increased proteolytic (breakdown) 
activity of collagen, rather than a decrease in synthesis of collagen thus rendering 
the interfibrillar bonds weak.2,6,7  
 
The central or paracentral thinning can lead to tears in descemets membrane that 
allows aqueous humour to enter the corneal layers which leads to the 
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development of ‘acute hydrops’ and later, scarring.3 When the disease has 
reached the hydrops or scarred stage, patients require a corneal transplant 
(penetrating keratoplasty) to restore vision. At this stage, corneal collagen 
crosslinking is no longer indicated.7 
 
In order to prevent patients from undergoing a corneal transplant, the disease 
needs to be stopped at its initial stages, when the cornea begins to thin. Therefore 
the collagen within the stroma needs to be strengthened, by enhancing the 
collagen lamellae bonds. The procedure of choice is corneal collagen crosslinking. 
CXL is a procedure that increases corneal rigidity and integrity.7,8 It is indicated in 
patients with structurally weak collagen binding within the corneal stroma, such as 
ectasias, like in the case of keratoconus and even post-lasik ectasia. 
 
Dr Gregor Wollensak introduced CXL, in a 3year long pilot study (started in 1998) 
carried out in Dresden, Germany.9 He was inspired by the widespread polymer 
industry that used crosslinking to stabilize tissue. This was evident in the collagen 
based bioprosthesis used for heart valves and physical crosslinking by Ultraviolet 
A light which is often used in dentistry to harden teeth fillings.10,11,12 Individuals 
who are ’protected’ against developing keratoconus are, diabetics and the aged, 
as crosslinking of collagen occurs by advanced glycation endproducts for diabetics 
and the naturally occurring age-related crosslinking process that takes place in the 
aged.10 
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Over the last decade, CXL has become a procedure of choice for the management 
of keratoconus and other corneal ectasias. The aim of CXL is to stop or slow down 
the progression of corneal ectasias. This then reduces the need for corneal 
transplantation. The mechanism of CXL is combining Riboflavin (Vitamin B2) 0.1% 
and Ultraviolet A light (UVA). This leads to strengthening of the interlamellar and 
intralamellar collagen fibril adhesions between adjacent collagen lamellae.8 
 
Ribloflavin has a triple action; it acts as a photosensitiser to produce free oxygen 
radicals or reactive oxygen species (ROS), it absorbs the UVA irradiation and it 
lubricates the cornea at the same time.13 It is non-toxic and easily penetrates the 
cornea in the absence of an epithelium.11 It is available in the form of a topical (eye 
drop) preparation. 
 
The free oxygen radicals cause photo-oxidative damage of cells i.e. apoptosis 
(death) of keratocytes and induces chemical covalent crosslinkage bonds between 
collagen fibrils via the lysyl oxidase pathway.8 In this manner, collagen fiber 
diameter increases and the mechanical strengthening of collagen takes place.13 
Wollensak et al, describes an average increase in collagen fiber diameter of 
12.2% in the anterior stroma and a 4.6% increase in the posterior stroma of 
treated corneas.12,13 
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The UVA light on the other hand causes an increase in intra and interfibrillar 
covalent bonds by photosensitized oxidation.14 Normally, the cornea would absorb 
30% of the UVA light and 50% is absorbed by the lens. When combining a 
photosensitiser like riboflavin, as much as 95% of UVA light is absorbed within the 
cornea. This enhances the mechanism of collagen strengthening and at the same 
time protects the posterior structures (corneal endothelium, lens and retina) from 
irradiation.14,15 Most changes take place within the anterior 300 µm of the cornea, 
accounting for a 328% increase in the tensile rigidity after CXL.8     
 
Apart from increasing corneal strength, the effect of combined riboflavin/UVA 
prevents viral and bacterial replication.14 There are many indications for this 
procedure, but this research will focus on CXL for keratoconus patients.   
 
Specific criteria needed for the crosslinking procedure are: 8,12,16 
 Patients under the age of 35 years 
 Best corrected visual acuity (BCVA) worse than 6/7.5 
 Corneal thickness > 400 µm 
Screening parameters that studies looked at prior to CXL, included: 7,9,11,12,18,20 
Best corrected visual acuity (BCVA), corneal topography (corneal curvature), 
intraocular pressure (IOP) measurement, keratometry measurements (K1 and K2), 
central corneal endothelial cell density, corneal photography, slit lamp 
 6 
 
examination, fundus examination and preoperative pachymetry (corneal thickness 
more than 400 µm is required). 
Postoperatively the same parameters were assessed as outcome measures of the 
procedure.  
 
The technique of CXL is simple and easy to perform: 8,9,10,12,14 
 CXL is a sterile procedure, carried out preferably in an operating 
theatre. 
 Instillation of 4 drops of Ofloxacin 0.3% (antibiotic) and 2 drops of 
Pilocarpine 2% into the treatment eye. 
 Topical anaesthetic drops are applied.  
 Pachymetry is carried out in 5 consecutive measurements, on the 
thinnest part of the cornea ensuring that it is not less than 400 µm. 
 Debridement of the central 7.0 - 9.0 mm of the corneal epithelium.  
 Iso-osmolar Riboflavin 0.1% solution (10mg riboflavin-5-phosphate in 
10ml dextran T-500 20% solution) is applied to the cornea every 4-5 
minutes for 30 minutes. 
 After the first 30 minutes, ultrasound pachymetry is repeated to 
ensure the stroma is still 400 µm thick. If it is less than 400 µm, then 
0.1% riboflavin in hypo-osmolar saline solution is used instead and 
applied every 4-5 minutes for 30 minutes. The pachymetry is 
rechecked after this. 
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 Penetration of riboflavin into the anterior chamber is viewed by 
performing slit lamp biomicroscopy and looking for a ‘yellow’ flare in 
the anterior chamber.14 
 Irradiation with UVA light of 370nm is applied for 30minutes to the 
eye at a working distance of 54mm with an irradiance of 3mW/cm2. 
 During the UVA treatment, 0.1% riboflavin solution is instilled every 
4-5 minutes, and topical anaesthetic is instilled when necessary. 
 After treatment, antibiotic ointment/drops are administered and a 
bandage contact lens is applied to the eye. 
The method of CXL described above is known as the ‘epi-off (epithelium off) CXL 
or classic CXL’ proposed by Gregor Wollensak. 
 
More recently there has been literature published on CXL not involving the 
removal of the central epithelium, also known as ‘epi-on (epithelium on) CXL or 
transepithelial CXL’. The difference with this type of CXL is the use of 
transepithelial riboflavin (riboflavin TE or Ricrolin TE) specially formulated with 
trometamol (Tris-hydroxymethyl aminomethane), 0.01% sodium 
ethylenediaminetetraacetic acid (EDTA) and occasionally 0.3% gentamicin and 
benzalkonium chloride.17,18,19 Ricrolin TE solution is thought to enhance the 
penetration of riboflavin through the epithelium without debridement of the central 
epithelium. The exposure time remains the same at 30minutes with a 3mW/cm2 of 
UVA exposure. 
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In view of not having to debride the epithelium, this technique has been favoured 
in the paediatric population and those with a corneal thickness of ≤ 400 µm.17,18 
The postoperative management is similar to the epi-off CXL technique. It differs 
only because there is no insertion of a bandage contact lens after the epi-on 
procedure. 
 
The postoperative follow-up proposed by Jankov II et al, for epi-off CXL suggest 
that visits take place on day 1 and 5, then at 1, 6 and 12 months.14 On day 1 
topical antibiotic is prescribed. It is used 4 times a day for 1 week. Topical steroid 
use immediately postoperatively is debatable and surgeon dependant. Jankov II et 
al further describes, removing the bandage contact lens on day 3 postoperatively 
and the patient is then instructed to use a topical steroid on day 3, which will be 
tapered over the course of 2 months.14  
 
Outcomes demonstrated by Wollensak et al over a period of 4 years showed that 
the best corrected visual acuity (BCVA) improved by an average of 1.26 snellen 
lines (visual acuity) and the average flattening of keratometry readings were 2.01 
diopters.9 The Siena Eye Cross Study performed in Italy, were able to show 
comparable outcomes after their 5 year follow up post CXL. They demonstrated a 
mean keratometry reduction of 2 diopters, a mean best spectacle corrected visual 
acuity (BSCVA) improvement of 1.9 snellen lines and an unaided visual acuity 
(UnVA) improvement of 2.7 snellen lines over 5 years.20 
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It is evident that CXL is a relatively safe and minimally invasive procedure for the 
treatment of keratoconus with promising outcomes. It is frequently indicated in the 
early stages of keratoconus. CXL can be beneficial in preventing future corneal 
transplantation and assist with potentially minimising the waiting lists for corneal 
transplants. A South African study by Makgotloe and Carmichael revealed that 
easier payment for corneas favour its distribution to the private rather than the 
public sector, due to the lack of procurement programmes for corneal donations in 
public hospitals.21 
 
Thus if CXL is performed at the earlier stages of keratoconus, it can reduce the 
need for future corneal transplants, and perhaps reduce the burden of long waiting 
lists for corneal transplants in the public sector due to affordability issues. 
 
1.2 RESEARCH AIM 
The aim of this research report was to analyse the visual acuity and keratometry 
readings in keratoconus patients before and after classic ‘epi-off’ CXL in order to 
establish the efficacy of crosslinking in halting or slowing down the progression of 
keratoconus. 
 
1.3 RESEARCH OBJECTIVES 
a) To compare the outcomes of visual acuity and keratometry readings 
(corneal curvature flattening) before and after CXL. 
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b) To determine the degree of improvement in visual acuity and degree of 
corneal curvature flattening after performing CXL. 
c) To determine which group of keratoconus patients benefitted most from 
the procedure. 
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CHAPTER 2 
 
2.0 METHODOLOGY 
2.1 STUDY DESIGN 
The study comprised a retrospective review of the pre-CXL and post-CXL visual 
acuity and keratometry readings of patients with keratoconus who underwent CXL 
in the period, January 2009 to July 2011at private practices of four 
ophthalmologists. Patient records were the source of the relevant data captured. 
 
2.2 DATA COLLECTION 
The data collected was a review of patient records from four private 
ophthalmologists. 
Consent for data collection was given by each ophthalmologist at their practices 
(Appendix B). The patient records were viewed between October 2011 and 
January 2012. 
This proposed study had received ethical approval from the Human Research 
Ethics Committee (Medical), University of the Witwatersrand on the 29/07/2011. 
A clearance certificate was issued, Reference M110717 (Appendix A). 
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Each patient record was captured on a data sheet (Appendix C) manually and 
thereafter captured onto an Excel spread sheet for purposes of statistical review. 
Data recorded fell under three periods of time: Pre-CXL, 3 months post-CXL and 6 
months post-CXL. 
 
2.2.1 INCLUSION CRITERIA 
a) Patients diagnosed with keratoconus in one or both eyes. 
b) Patients who had undergone CXL in one or both eyes. 
c) All patients were 18 years and older. 
 
2.2.2 EXCLUSION CRITERIA 
Inadequate patient record keeping. 
Patients who underwent a corneal transplant before the 6 months post-CXL follow 
up. 
 
2.2.3 STUDY POPULATION 
This consisted of 41 eyes of 29 patients that underwent CXL between January 
2009 and July 2011. 
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2.2.4 DATA MANAGEMENT 
Records of patients meeting the inclusion criteria were reviewed. Relevant data 
were extracted from each record by the primary researcher and then captured 
onto a spread sheet in Microsoft Office Excel 2007.  
A master data sheet containing the name of the patient who was linked to the 
numbered data capture sheet was kept separately. Only the primary researcher 
had access to the data sheets. This was done to ensure patient anonymity.  
For this purpose, each eye of the patient that had undergone CXL was numbered 
separately. 
  
The following data were extracted from each record: 
a) Date of crosslinking 
b) Eye that was crosslinked 
c) Sex of the patient 
d) Age of the patient 
e) Medical history 
f) Ocular allergy being a risk factor for the development of keratoconus 
g) Pre-CXL measures:   
Unaided visual acuity (UnVA) 
Best corrected visual acuity (BCVA) 
Keratometry readings (Pentacam based) 
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h) Post-CXL follow up at 6 months: 
  Unaided visual acuity (UnVA) 
  Best corrected visual acuity (BVCA) 
  Keratometry readings (Pentacam based) of the CXL eye 
i) Keratoconus grouping (based on keratometry readings in dioptres):   
Mild (≤47 D) 
Moderate (48 - 54 D) 
Advanced (≥55 D) 
 
2.3 DATA ANALYSIS 
Data was analysed using Stata 12 software. 
Descriptive analysis of the data was carried out as follows: Categorical variables 
were summarised by frequency and percentage, and illustrated by means of bar 
charts. Continuous variables were described by mean, standard deviation, 
median, interquartile range and histogram.  
A paired t-test was used to compare visual acuity and keratometry readings before 
crosslinking and 6 months after crosslinking. Where the assumptions of the test 
were not met, the Wilcoxon matched paired test was used instead. 
A 5% significance level was used (p < 0.05 was regarded as significant). 
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2.4 STAFF AND ADMINISTRATION 
This study was conducted by Dr Taruna Rowjee (registrar) and supervised by Dr 
Darshana Soma (consultant) from Ophthalmology (Department of the 
Neurosciences). Co-supervised by Prof Trevor Carmichael (HOD of 
Ophthalmology) 
Records from four private ophthalmologists were reviewed, namely: 
Professor I Mayet (Garden City Hospital) 
Dr R Daniel (Morningside Hospital) 
Dr A dos Ramos (Optimed in Alberton) 
Dr E Jervis (Optimed in Alberton).  
Each ophthalmologist gave written consent for the review of their relevant patient 
records (Appendix B). 
 
2.5 ETHICAL CONSIDERATIONS  
An Ethics clearance certificate was issued by the Wits Human Research ethics 
Committee in July 2011. The ethics protocol number is M110717 (Appendix A).  
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CHAPTER 3 
 
3.0 RESULTS   
3.1 PATIENT BASELINE VARIABLES 
Forty-one eyes of 29 patients were reviewed. All 29 patients underwent the classic 
‘epi-off’ CXL. 12 patients had both eyes crosslinked at separate times and the 
remaining 17 patients had one eye crosslinked.  
 
3.1.1 PATIENT DEMOGRAPHICS  
3.1.1.1 GENDER 
Of the 29 patients, 20(69%) were males and 9(31%) were females. 
 
Figure 1. Gender distribution 
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3.1.1.2 AGE 
The median age of the 29 patients is 29 years (interquartile range: 21, 37 years). 
The ages of the patients ranged from 18 to 55 years. 
 
Figure 2. Age distribution of the patients 
 
3.1.2 LATERALITY  
Of the 41 eyes that underwent CXL, 24(59%) were right eyes and 17(41%) were 
left eyes. 
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3.1.3 MEDICAL HISTORY 
Ocular allergy is a common predisposing condition for the development of 
keratoconus. In this study however, only 3(10%) of the 29 patients had a history of 
ocular allergy. 
 
3.2 OUTCOME MEASURES 
This study looked at the visual acuity and keratometry readings post-CXL. The 
pre-CXL versus 6 months post-CXL visual acuity and keratometry readings were 
compared. We wanted to determine if visual acuity improved and keratometry 
readings flattened at 6 months after CXL. 
The study further analysed which group of keratoconus patients benefited most 
from CXL and this was determined by an improvement or no change in visual 
acuity and keratometry readings, which implied a halt in progression of 
keratoconus. 
 
3.2.1 VISUAL ACUITY: PRE-CXL COMPARED TO 6 MONTHS POST-CXL 
The LogMar scale of visual acuity was used. The amount of lines gained or lost is 
showed as Snellen equivalent. 
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3.2.1.1 UNAIDED VISUAL ACUITY (UnVA) 
Before treatment, the median UnVA was 0.3 (interquartile range: 0.1, 0.6). After 
CXL the median UnVA at 6 months was 0.3 (interquartile range: 0.15, 0.7). The 
change in UnVA from pre-CXL to 6 months post-CXL was not significant (p = 
0.07).  
The graph below demonstrates that of the 41 eyes in total, 16(39%) eyes showed 
an improvement in UnVA at 6 months, 17(41%) eyes showed no change(same), 
and 8(20%) eyes showed a decrease in UnVA at 6 months, compared to pre-CXL 
values. 
 
Figure 3. Percentage of eyes showing change in UnVA at 6 months 
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3.2.1.2 BEST CORRECTED VISUAL ACUITY (BCVA)  
Before treatment, the median BCVA was 0.8 (interquartile range: 0.6, 1.0). After 
CXL the median BCVA after 6 months was 0.9 (interquartile range: 0.6, 1.0). The 
change in BCVA from pre-CXL to 6 months post-CXL was not significant (p = 
0.45).  
The graph below demonstrates that 12(29%) eyes showed an improvement in 
BCVA at 6 months, 18(44%) eyes showed no change(same), and 11(27%) eyes 
showed a decrease in BCVA at 6 months, compared to pre-CXL values. 
 
Figure 4. Percentage of eyes showing change in BCVA at 6 months 
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3.2.2 KERATOMETRY READINGS (CORNEAL CURVATURE) 
Before treatment, the median corneal curvature was 45.50 (interquartile range: 
44.00, 48.85). After CXL the median corneal curvature after 6 months was 45.50 
(interquartile range: 44.00, 48.30). The change in corneal curvature from pre-CXL 
to 6 months post-CXL was not significant (p = 0.48). 
After CXL of the 41 eyes at 6 months, 23(56%) eyes had an average flattening of 
corneal curvature readings of 0.7 D and the remaining 18(44%) eyes showed 
more steepening (worsening) of the corneal curvature readings of 0.9 D. 
 
Figure 5. Percentage of eyes showing flattening vs steepening of corneal 
curvature at 6 months 
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Figure 6. Corneal curvature at 6 months after CXL, measured in diopters 
 
3.2.3 KERATOCONUS GROUPS BASED ON KERATOMETRY READINGS 
41 eyes were graded as mild (≤47 D), moderate (48-54 D) or advanced (≥55 D) 
keratoconus.  
The graph below demonstrates that of the 41 eyes, 30(73%) eyes showed mild 
keratoconus, 7(17%) showed moderate keratoconus and 4(10%) showed 
advanced keratoconus. 
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Figure 7. Keratoconus grades based on keratometry readings 
 
19 of the 30 eyes in the mild keratoconus group (73%) showed an average 
flattening of corneal curvature of 0.6 D. The remaining showed no change. 
4 of the 7 eyes in the moderate keratoconus group (17%) showed an average 
flattening of corneal curvature of 0.7 D. The remaing 3 eyes showed no change. 
All 4 patients in the advanced group (10%) had steepening of their corneal 
curvatures with an average of 1.2 D of steepning. The maximum amount of 
steepening of corneal curvature was 3.0 D in 1 patient. 
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CHAPTER 4 
 
4.0 DISCUSSION 
Keratoconus is a progressive ectasia, with an incidence of 1 in 2000, typically 
beginning during puberty and naturally regressing by the 3rd to 4th 
decade.4,6,7,8,9,10,15,17 Progression of the disease, both hereditary and acquired 
forms, needs to be controlled to avoid having to resort to performing a corneal 
transplant.7,18 For this purpose corneal collagen crosslinking has shown to slow 
down the progression of keratoconus.7,8,12,13 CXL has also been used for the 
treatment of pellucid marginal degeneration, prophylactically for the treatment of 
iatrogenic keratectasia and for the treatment of infectious corneal ulcers.14 
Keratoconus progression is said to halt or slow down when visual acuity increases 
or remains the same, and if corneal curvature readings (keratometry) flatten or 
remain the same, after collagen crosslinking. 
The classic or ‘epi-off’ crosslinking has been trialled by the likes of Gregor 
Wollensak, Theo Seiler and Eberhard Spoerl, the pioneers in this 
procedure.9,10,11,13 More recently transepithelial or epithelium-on CXL has been 
favoured for the paediatric population.17,18,19 Our study focuses on the outcomes 
after epithelium-off or classic CXL in keratoconic patients and its effects on vision 
and corneal curvature. The classic CXL technique has proven to be safe, as 
riboflavin acts as a protective barrier for other intraocular structures (endothelium, 
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lens and retina), absorbing the UVA light exposed to the cornea in order for CXL to 
take place.23   
 
Our keratoconic population showed a male predominance of 69% which has been 
found in similar studies.6,7,18,19,22 Ocular allergy with chronic eye rubbing has been 
found to play a role in the etiology of keratoconus,4,8 however in our study, there 
were few patients (3%) with ocular allergy.  
 
The median age of the patients was 29 years. Our inclusion criteria included 
patients 18 years and older, with the youngest being 18 years and the oldest 55 
years. Even though keratoconus is known to start at puberty, for consent purposes 
we chose to only include those patients 18 years and above. It was found that 
diagnosing keratoconus in the paediatric age group, had a poorer prognosis due to 
rapid disease progression and ultimate corneal transplant.18 None of our patients 
had undergone or needed to be scheduled to have a corneal transplant at their 6 
months of follow up. 
 
Considering the outcomes of CXL, which includes vision and corneal curvature, 
our study focused on these at 6 months after crosslinking. Both the change in 
UnVA and BCVA after CXL from pre-CXL to 6 months post-CXL were not 
statistically significant. This could be due to the small population size and/or the 
short follow up duration. Similar studies in the literature had significant 
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improvement in visual outcomes. The follow up periods differed in each study.7,9,10, 
24,25,26,27,28 One of the first studies that followed patients up for 4 years, treated 23 
eyes with crosslinking showed a 2.01 D flattening of corneal curvature and 65% of 
the eyes had a slight improvement in vision at the end of the 4 years.9  
Our study however showed that approximately 20% of eyes had a decrease in 
visual acuity (UnVA and BCVA) after 6 months, which meant the remaining 80% 
had either an improvement or no change in vision when comparing before and 
after CXL at 6 months. 
UnVA improved in 39% of eyes with a 1.3 Snellen line improvement while 41% of 
eyes showed no change in their unaided visual acuity at 6 months. BCVA 
improved by 1.2 snellen lines in 29% of eyes and 44% of eyes had no change at 
the end of 6 months follow up. With these results after 6 months we have been 
able to determine that keratoconus progression can at least be halted by either 
improving vision slightly or keeping the vision unchanged after the crosslinking. 
 
Corneal curvature flattening occurred in 56% of patients with an average flattening 
of 0.7 D. The largest flattening of corneal curvature was 2.85 D in 1 patient, very 
similar to Wollensak et al with 2.01 D average.9 When looking at other similar 
studies, their mean corneal curvature flattening values were around 2.0 D, which 
was significant.7,9,10,24,25,26,27,28 Even though corneal curvature flattening was not 
significant in our study, just more than half the eyes (56%) in this study had 
corneal curvature flattening.  
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The table below summarises similar studies. It is apparent that the above studies 
had similar corneal curvature flattening values. The visual acuity values were also 
similar. They all however had more than a 6 month follow up period. The study 
that is probably the most similar to this study is the Turkish study by Coskunseven 
et al.7  
 
 Number of 
eyes 
Follow-up 
period 
Average corneal 
curvature  
flattening 
Visual acuity 
improvement 
Wollensak 
20039  
(Germany) 
 
23 
 
4 years 
 
2.01D 
 
1.26 lines 
Coskunseven 
20087  
(Turkey) 
 
38 
 
9 months 
 
2.01D 
 
1 line 
Hersh  
201128  
(USA) 
 
49 
 
1 year 
 
≥2.0 D 
 
≥2 lines 
 
Table 1. Similar studies showing their outcomes after CXL 
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Our study looked at another aspect of keratometry readings by separating the 41 
eyes into keratoconus severity groups. This enabled us to determine which group, 
based on the keratometry readings showed promising results at 6 months.  
Of the 23 eyes that had the 0.7 D flattening in keratometry readings, 19 eyes were 
in the mild keratoconus group and 4 eyes were in the moderate keratoconus 
group. In the mild keratoconus group of 19 eyes, 4 eyes had a 1.3 snellen line 
improvement in vision. The advanced keratoconus group (4 eyes) had steepening 
of corneal curvature with an average of 1.2 D and a maximum of 3.0 D in 1 patient. 
 
Even though corneal curvature did not flatten significantly (p= 0.48), in this study, 
the groups that at least had some improvement or no change at all in both visual 
acuity and corneal curvature flattening were the mild and moderate keratoconus 
groups. Performing CXL on these groups may be beneficial in halting the process 
earlier rather than later. The advanced keratoconus group did not show any 
benefit from performing CXL. 
 
By treating keratoconus in its mild to moderate form, the disease may at least be 
halted and the need for later corneal transplants (penetrating keratoplasty) can be 
minimised. Makgotloe and Carmichael (South African study) showed that the 
availability of corneal tissue for keratoplasty favours that of private healthcare.21 
The need for corneal tissue can be minimised if keratoconus is treated earlier. 
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Agrawal also raised a similar finding in an Indian study that also revealed the lack 
of tissue availability for transplants.24 
 
Our study proves that corneal collagen crosslinking offers a non-invasive 
treatment option for patients suffering with keratoconus. With improvement in 
visual acuity and minimal corneal curvature flattening, keratoconus can at least be 
halted and the need for keratoplasty can be decreased. The mild and moderate 
group of keratoconus patients benefit most from CXL.  
 
Limitations in this study were, the small population size and the short follow up 
period. A larger, long-term prospective study would probably be a good follow on 
from this. A comparative study, looking at transepithelial versus classic CXL would 
also assist with deciding which of the 3 groups of keratoconus patients improve 
most in visual outcome post-CXL.   
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CHAPTER 5 
 
5.0 CONCLUSION 
Corneal collagen crosslinking is a good treatment option for patients with 
keratoconus. It is safe, non-invasive and it halts keratoconus by flattening corneal 
curvature and in improving visual acuity even at the slightest. The patients benefit 
most when keratoconus is treated earlier during the mild to moderate stages of 
keratoconus, rather than in the advanced form. If earlier treatment is carried out, 
the need for future corneal transplants can be decreased and this can assist with 
eliminating tissue availability issues that may arise especially for the public sector.  
 
 
 
 
 
 31 
 
APPENDIX A
 
 32 
 
APPENDIX B 
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APPENDIX C 
Data capture sheet 
Eye number: _______   Involved eye: _____    Date of CXL: ______    Age: ___ 
Sex: M ___   or F ___ Medical History: _____________________________ 
Examination before CXL (pre-CXL):   Post-CXL at 6 months: 
(Right) Eye  (Left)             UnVA 
          UnVA           BCVA 
          BCVA     K1          Keratometry       K1 
K1          Keratometry          K1   K2          K2 
K2           K2        
         Cornea 
       AC         
           IOP             
          Lens             
     Fundoscopy    
1 month post-CXL               
        UnVA 
        BCVA 
K1          Keratometry  K1 
K2    K2 
Future management plan: _____________________________________________ 
UnVA: Unaided visual acuity  BCVA: Best corrected visual acuity  
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